INTRODUCTION
============

Sarcoidosis is a multisystem, multiorgan disease of unknown etiology and unpredictable course. It is characterized by noncaseating granulomas that can involve any organ system and can affect persons of all races and ages.^(^ [@B01] ^)^

Albeit a disease with a low mortality rate, sarcoidosis can become a chronic malady in which patients develop various physical and mental disabilities.^(^ [@B01] ^-^ [@B03] ^)^ The majority of sarcoidosis patients experience spontaneous disease remission within 2-5 years of diagnosis.^(4)^ However, 10-30% of sarcoidosis patients develop chronic symptoms or progressive disease that can affect physical functioning and emotional well-being.^(^ [@B04] ^-^ [@B07] ^)^

Previous studies in sarcoidosis have focused on the pulmonary manifestations of the disease, as assessed by chest imaging and pulmonary function testing during the evolution of the disease.^(^ [@B08] ^-^ [@B10] ^)^ These clinical variables do not always predict long-term outcomes. For the individual patient, chest X-rays and spirometry correlate poorly with perceived quality of life.^(^ [@B11] ^)^ Reports describing health status and quality of life in sarcoidosis are limited to a few cross-sectional studies conducted in northern Europe or in the United States,^(^ [@B02] ^,^ [@B05] ^,^ [@B12] ^-^ [@B17] ^)^ in which a variety of generic and respiratory-specific questionnaires have been used.^(^ [@B02] ^,^ [@B05] ^,^ [@B18] ^-^ [@B23] ^)^ Our group previously reported results from the use of generic and respiratory-specific instruments for quantifying health status and quality of life in a cross-sectional study of sarcoidosis patients in Serbia.^(^ [@B24] ^,^ [@B25] ^)^

Five large-scale studies conducted in Europe reported impaired health status and quality of life in patients with sarcoidosis, in whom physical, emotional, and even social functioning were found to be limited, as they have been in other studies.^(^ [@B02] ^,^ [@B12] ^-^ [@B19] ^)^ In the largest study of its kind conducted in the United States,^(^ [@B26] ^)^ health status was assessed in 120 sarcoidosis patients with a variety of instruments, including the Medical Outcomes Study 36-item Short-Form Health Survey, the Saint George\'s Respiratory Questionnaire, the Center for Epidemiologic Studies Depression Scale, and the Perceived Stress Scale.^(^ [@B20] ^,^ [@B26] ^-^ [@B28] ^)^

To our knowledge, there have been no studies specifically evaluating health status in sarcoidosis patients in Central or Eastern Europe. Therefore, the primary aim of this study was to evaluate the health status of sarcoidosis patients with the first disease-specific sarcoidosis questionnaire-the self-report Sarcoidosis Health Questionnaire (SHQ)-published in 2003 by a group of authors working in the United States.^(^ [@B29] ^)^ Additional objectives were to assess the health status of sarcoidosis patients according to the treatment regimen and to assess the feasibility of using the SHQ in non-English-speaking sarcoidosis patients.

METHODS
=======

Study design and patient sample
-------------------------------

This was a cross-sectional study. The majority of patients recruited to participate in this study were registered with the Serbian Association of Sarcoidosis, which includes 1,562 patients with various clinical forms of sarcoidosis. We enrolled 346 patients with biopsy-confirmed sarcoidosis, diagnosed at the Clinic for Pulmonology of the Clinical Center of Serbia, in the city of Belgrade, Serbia. The patients were examined at regularly scheduled clinical visits, during which they voluntarily completed the SHQ and underwent spirometry. The study was approved by the local research ethics committee, and all of the patients gave written informed consent.

Health status instrument
------------------------

The SHQ^(^ [@B29] ^)^ is a 29-item, self-report questionnaire with responses ranging from \"all of the time\" (score of 1) to \"none of the time\" (score of 7). Higher scores indicate better health status. It takes approximately 10 min to complete the SHQ. This instrument measures three health status domains: daily functioning, physical functioning, and emotional functioning.

The original version of the SHQ was kindly provided to the Serbian Association of Sarcoidosis by Dr. Christopher Cox, of Duke University Medical Center. The instrument was officially translated into Serbian and adapted for use in Serbia with the assistance of two native-speaking language experts-one native speaker of Serbian and one native speaker of English-who worked independently on the translation from English to Serbian and the back-translation from Serbian to English, respectively.

Procedures
----------

Patients completed the SHQ during their regularly scheduled clinical visits, undergoing pulmonary function testing on a spirometer (MasterLab; Jaeger, Würtzburg, Germany), in accordance with the American Thoracic Society/European Respiratory Society guidelines,^(^ [@B30] ^)^ on the same day. We used the European Respiratory Society criteria for lung function impairment.^(^ [@B31] ^)^ We measured DLCO using the single-breath method.^(^ [@B32] ^)^

Using the organ index devised for the \"A Case Control Etiology of Sarcoidosis Study\",^(^ [@B33] ^,^ [@B34] ^)^ we assessed the current extent of organ involvement in our sarcoidosis patients. The diagnosis of sarcoidosis in any organ system was classified as definite, probable, or possible. Positive organ involvement encompassed the criteria for a definite or probable diagnosis, in accordance with the index cited above.

Treatment
---------

Based on the clinical outcome, the patients were stratified into two groups: acute sarcoidosis (disease duration \< 2 years), comprising 137 patients (39.6% of the sample); and chronic sarcoidosis (disease duration ≥ 2 years), comprising 209 patients (60.4% of the sample). Among the 346 patients, the recommended treatment regimen was monotherapy with prednisone in 246 (71.1%) and monotherapy with methotrexate in 67 (19.5%). In the chronic sarcoidosis patients, methotrexate was used as monotherapy or as a corticosteroid sparing agent (in combination with 5-10 mg/day of prednisone as maintenance therapy). No treatment was required in 33 patients (9.5%), 21 (63.6%) of whom were acute sarcoidosis patients, the remaining 12 (36.4%) having chronic, asymptomatic sarcoidosis.

Statistical analysis
--------------------

To compare SHQ scores with the clinical characteristics of patients, we used two-sample t-tests for variables with two categories and one-way ANOVA for variables with more than two categories. Correlations were calculated by either the Pearson or Spearman method. Independent variables were considered significant at the p \< 0.05 level in the univariate analyses and were assessed as a single block in multivariate regression models. Because SHQ scores are continuous data, we used multiple linear regression analysis in order to evaluate the contribution of risk factors to the total SHQ score or the score for each of its three domains. We used a stepwise model (backward elimination of variables) in which values of p \< 0.05 indicated statistical significance. The variables evaluated in the multiple linear regression analysis included age (decade of life), gender, parenchymal lung disease on chest X-ray, the course of the disease (acute vs. chronic), extrapulmonary disease, specific system involvement (cutaneous, neurological, or cardiac disease), FVC, DLCO, carbon monoxide transfer coefficient, and the treatment regimen (prednisone alone, methotrexate alone, or a combination of the two). Statistical analyses were performed with the Statistical Package for the Social Sciences, version 10.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

[Table 1](#t01){ref-type="table"} summarizes the characteristics of the study patients. At the time of the administration of the SHQ, 33 (9.5%) of the 346 patients were asymptomatic. The remainder reported a variety of health problems, including low energy, fatigue, an undefined feeling of bodily pain, chest tightness, joint pain, and muscle discomfort.

Table 1.Demographic and clinical characteristics of the patients.^a^**CharacteristicN = 346**Age (years), mean ± SD46.03 ± 10.8GenderFemale257 (74.3)Male89 (25.7)EthnicityWhite346 (100.0)Symptomatic patients313 (90.5)Stage of the lung disease0 or 1 (no parenchymal lesions)233 (67.3)2-4 (with parenchymal lesions)113 (32.7)Pulmonary sarcoidosis337 (97.4)Extrapulmonary sarcoidosis122 (35.3)Number of organ systems involved, mean (range)3 (1-5)Extrapulmonary organ systems involvedEye68 (19.7)Skin50 (14.5)Heart23 (6.7)Nervous system (neurosarcoidosis)22 (6.4)Liver16 (4.6)Spleen12 (3.5)Bone11 (3.6)Bone marrow1 (0.3)Course of the sarcoidosisAcute137 (39.6)Chronic209 (60.4)Lung functionRestrictive lung disease (FVC \< 80%)244 (70.5)Obstructive lung disease (FEV~1~/FVC ratio \< 70%)10 (2.9)Normal92 (26.6)TreatmentNone33 (9.5)Prednisone only246 (71.1)Methotrexate only21 (6.1)Methotrexate plus prednisone46 (13.3)[^1]

Most-337 (97.4%)-of the patients had pulmonary involvement, whereas 122 (35.3%) also had extrapulmonary involvement. Among the 122 patients with extrapulmonary disease, the sarcoidosis affected one organ in 73 (59.8%), two organs in 30 (24.6%), and three or more organs in 19 (15.6%).

Patients with chronic sarcoidosis had significantly lower scores, indicating poorer health status, for all domains of the SHQ ([Table 2](#t02){ref-type="table"}). Erythema nodosum was seen in 21 (15.3%) of 137 patients with acute sarcoidosis. Although those patients were expected to show impaired physical functioning, due to polyarthralgia and (in some cases) fever, that was not found to be the case.

Table 2.Clinical characteristics of sarcoidosis and Sarcoidosis Health Questionnaire scores.^a^**Characteristic of sarcoidosisnSarcoidosis Health Questionnaire scoresDomainsTotalDaily functioningPhysical functioningEmotional functioning**CourseAcute1374.80 (0.87)5.00 (0.95)4.35 (0.76)4.72 (0.72)Chronic2094.16 (0.86)4.43 (1.07)4.13 (0.72)4.24 (0.75)p\*\< 0.001\< 0.001\< 0.05\< 0.001LocationExtrapulmonary1224.14 (0.89)4.45 (1.09)4.12 (0.77)4.24 (0.77)Exclusively pulmonary2444.58 (0.90)4.77 (1.02)4.26 (0.79)4.53 (0.76)p\*\< 0.001\< 0.05\> 0.05\< 0.001Stage of the lung disease0 or 1 (no parenchymal lesions)2334.52 (0.93)4.78 (1.03)4.25 (0.81)4.52 (0.78)2-4 (with parenchymal lesions)1134.19 (0.85)4.40 (1.08)4.14 (0.75)4.24 (0.74)p\*\< 0.05\< 0.05\> 0.05\< 0.05[^2]

Patients were evaluated by decade of life, stratified into seven groups ([Table 3](#t03){ref-type="table"}). The SHQ scores differed significantly among the age groups for the daily functioning domain (ANOVA F = 3.85; p \< 0.001) and for the physical functioning domain (ANOVA F = 4.49; p \< 0.001), as did the total SHQ score (ANOVA F = 4.59; p \< 0.001), although no such difference was found for the emotional functioning domain. The 114 patients in the 41- to 50-year age group had the lowest total SHQ scores, as well as the lowest scores for the daily functioning and physical functioning domains, whereas the 122 patients between 51 and 70 years of age had the lowest scores for the emotional functioning domain. There were only 3 patients over 70 years of age ([Table 3](#t03){ref-type="table"}).

Table 3.Age of sarcoidosis patients (by decade of life) and Sarcoidosis Health Questionnaire scores.^a^**SHQ scoresDecade of life (years)11-2021-3031-4041-5051-6061-7071-80(n = 2)(n = 24)(n = 81)(n = 114)(n = 95)(n = 27)(n = 3)**DF domain4.69 (1.09)4.84 (0.84)4.73 (1.04)4.20 (0.84)4.32 (0.90)4.30 (0.69)4.41 (0.31)PF domain5.66 (0.47)5.11 (0.69)5.02 (1.04)4.42 (1.10)4.49 (1.05)4.61 (0.92)5.44 (0.42)EF domain4.95 (1.48)4.54 (0.75)4.34 (0.92)4.14 (0.73)4.12 (0.77)4.12 (0.65)4.36 (0.21)Total5.10 (1.01)4.83 (0.60)4.70 (0.85)4.25 (0.76)4.31(0.75)4.34 (0.59)4.74 (0.17)[^3]

Significant differences were found between the patients with parenchymal lung disease (i.e., those in sarcoidosis stages 2-4) and those without (those in stage 0 or 1), in terms of the scores for the SHQ domains daily functioning and physical functioning, as well as total SHQ scores, all of which were lower in the former group ([Table 2](#t02){ref-type="table"}). Patients in whom the sarcoidosis affected three or more organs had the lowest mean total SHQ score (3.82 ± 0.94), as well as the lowest mean scores for the domains daily functioning (3.72 ± 0.91), physical functioning (4.00 ± 0.98), and emotional functioning (3.74 ± 0.95). Only the total SHQ score differed significantly between the groups stratified by location/organ involvement. The 50 patients with chronic cutaneous sarcoidosis had significantly lower scores for the daily functioning domain (ANOVA F = 1.353, p = 0.05). Likewise, the 23 patients with cardiac sarcoidosis had significantly lower scores for the physical functioning domain (ANOVA F = 1.523, p = 0.041), and the 23 patients with neurosarcoidosis had significantly lower total SHQ scores (ANOVA F = 1.912, p = 0.05). However, we found no significant differences among those groups in terms of the scores for the emotional functioning domain.

The scores for the SHQ domains daily functioning and physical functioning were significantly lower among the 122 patients with extrapulmonary sarcoidosis than among those with pulmonary involvement only, as were the total SHQ scores (p \< 0.05 for all). We also found significant differences between the patients with normal lung function and those with restrictive lung disease (FVC \< 80%), in terms of the scores for the daily functioning domain (ANOVA F = 1.42; p = 0.019) and the physical functioning domain (ANOVA F = 1.47; p = 0.012), as well as the total SHQ score (ANOVA F = 1.41; p = 0.023), although we found no such difference in terms of the scores for the emotional functioning domain.

At evaluation, 246 (71.1%) of the 346 patients were under treatment with prednisone only; 21 (6.1%) were under treatment with methotrexate only; 46 (13.3%) were under treatment with the combination of methotrexate and low-dose prednisone; and 33 (9.5%) were not receiving any pharmacological treatment. The patients receiving monotherapy with prednisone had significantly higher SHQ scores for all domains than did those receiving monotherapy with methotrexate or combination therapy with methotrexate plus prednisone (p \< 0.05 for all). The 33 untreated patients had higher SHQ scores than did those receiving pharmacological treatment, the differences being statistically significant for all SHQ domains ([Table 4](#t04){ref-type="table"}). The patients treated with prednisone only were divided into those with acute sarcoidosis (n = 104) and those with chronic sarcoidosis (n = 142). The prescribed doses of prednisone were higher for those with acute disease than for those with chronic disease (20-30 mg/day vs. 5-10 mg/day). The mean daily functioning domain score, physical functioning domain score, and total SHQ score were significantly lower among the patients with chronic sarcoidosis than among those with acute sarcoidosis (p \< 0.05), although the mean emotional functioning domain score was not. Among the patients treated with prednisone, the mean emotional functioning domain score was higher in the acute sarcoidosis group (higher daily doses) than in the chronic sarcoidosis group (lower daily doses), as can be seen in [Table 5](#t05){ref-type="table"}.

Table 4.Comparison of Sarcoidosis Health Questionnaire scores, by treatment regimen.^a^**TreatmentnSarcoidosis Health Questionnaire scoresDomainsTotalDaily functioningPhysical functioningEmotional functioning**None334.71 (0.94)4.98 (1.11)4.33 (0.88)4.67 (0.82)Prednisone only2464.51 (0.93)4.78 (1.01)4.28 (0.79)4.52 (0.76)Methotrexate only214.15 (0.64)4.05 (0.96)3.93 (0.74)4.05 (0.58)Methotrexate plus prednisone463.86 (0.68)4.06 (1.04)3.93 (0.66)3.95 (0.67)F\*5.496.113.276.68p\*\< 0.0001\< 0.0001\< 0.05\< 0.0001[^4]

Table 5.Comparison of Sarcoidosis Health Questionnaire scores among prednisone-treated patients, by sarcoidosis course.^a^**Course of sarcoidosisnSarcoidosis Health Questionnaire scoresDomainsTotalDaily functioningPhysical functioningEmotional functioning**Acute^b^1044.79 (0.87)5.00 (0.94)4.37 (0.81)4.71 (0.71)Chronic^c^1424.27 (0.92)4.59 (1.04)4.21 (0.77)4.36 (0.77)p\*\< 0.0010.001\> 0.01\< 0.001[^5]

In the multivariate analysis, chronic disease and cardiac disease were both found to be independent predictors of lower scores for the SHQ domain daily functioning. Chronic disease, combination therapy (prednisone plus methotrexate), and neurosarcoidosis were found to be independent predictors of lower physical functioning domain scores, whereas female gender and prednisone monotherapy were found to be independent predictors of lower emotional functioning domain scores. As shown in [Table 6](#t06){ref-type="table"}, female gender, chronic disease, combination therapy, and neurosarcoidosis were significantly associated with lower total SHQ scores.

Table 6.Multiple linear regression analyses of various risk factors for lower Sarcoidosis Health Questionnaire scores.^a^**VariableMultiple linear regression analysesSHQ domain scoresTotal SHQ scoreDaily functioningPhysical functioningEmotional functioning**Gender (male vs. female)nsns−0.165 (0.003)−0.138 (0.010)Course (acute vs. chronic)−0.449 (0.004)−0.202 (0.000)ns−0.216 (0.000)Therapy (P vs. MTX vs. P+MTX)ns−0.153 (0.008)0.120 (0.041)0.143 (0.013)Neurosarcoidosisns0.116 (0.036)ns0.109 (0.046)Cardiac disease0.345 (0.024)nsnsns[^6]

DISCUSSION
==========

In the present study, we have assessed the health status of sarcoidosis patients using the first sarcoidosis-specific health status questionnaire (the SHQ). We found that, among the 346 sarcoidosis patients evaluated, health status was significantly impaired in all three SHQ domains (daily functioning, physical functioning, and emotional functioning).

The overall health status (total SHQ score) was significantly lower in the female patients in our sample. In addition, we noted that the proportion of patients with chronic disease was significantly higher among the female patients (77.5%) than among the male patients (68.8%), which could explain the significantly lower SHQ scores among the female patients. In the largest sarcoidosis health status study conducted in the United States, 87 (78.4%) of the 111 sarcoidosis patients evaluated were female, although the authors did not report poorer health status for the female patients.^(^ [@B26] ^)^ In the original SHQ validation study, involving 111 sarcoidosis patients, those same authors found no significant difference between the genders in terms of health status.^(^ [@B29] ^)^ Another recent study conducted in the United States showed significant gender differences for the SHQ physical functioning domain.^(^ [@B35] ^)^ In the present study, patients in the 41- to 50-year age group had the lowest SHQ scores. Unfortunately, those are often the most economically productive years and overall poor health status creates a burden for such patients. Although the mean age of the patients in the original SHQ validation study was approximately 45 years,^(^ [@B29] ^)^ the authors found no significant age-related difference in SHQ scores in their subsequent sarcoidosis health status study.^(^ [@B26] ^)^

The significantly lower SHQ scores in our patients with chronic sarcoidosis underscore the importance of patient perception of the burden of chronic sarcoidosis, predominantly in the daily functioning and emotional functioning domains. In the original SHQ validation study,^(^ [@B29] ^)^ the proportion of patients who characterized their health status as fair-48 (43.2%)-did not differ significantly from that of those who characterized it as poor-16 (14.4%). However, in the subsequent study conducted by the same authors, there was a statistically significant difference between the symptomatic patients and asymptomatic patients, in terms of the mean total SHQ score.^(^ [@B26] ^)^ In the present study, we found significant differences in the SHQ scores between the patients with acute sarcoidosis and those with chronic sarcoidosis, the former having significantly higher scores for all SHQ domains.

We also found that the scores for the daily functioning, physical functioning, and emotional functioning domains of the SHQ were inversely associated with the number of organ systems affected by sarcoidosis. Likewise, in the sarcoidosis health status study conducted in the United States, a higher the number of affected organs translated to lower SHQ scores.^(^ [@B26] ^)^

Because studies conducted in Europe have not utilized the SHQ, the results of those studies cannot be compared with those of the present study. However, comparing our results with those of the sarcoidosis health status study conducted in the United States, in which the SHQ was also employed, we noticed differences between the two patient samples. In the sample evaluated in the latter study, 80% of the patients were African American,^(^ [@B26] ^)^ which often correlates with clinical phenotypes that are associated with more severe disease, a more aggressive course, and a worse prognosis.^(^ [@B36] ^)^

One limitation of our study is that we evaluated health status only with a disease-specific instrument (the SHQ) and did not compare those findings with those that might have been obtained with instruments that are more generic or with respiratory-specific questionnaires. However, in a recent study involving a predominantly European population of sarcoidosis patients, the SHQ was shown to correlate well with measures of health-related quality of life and fatigue.^(^ [@B19] ^)^

In the original SHQ validation study conducted in the United States,^(^ [@B29] ^)^ the authors found that prednisone therapy was associated with lower SHQ scores and therefore with poorer health status. However, they were unable to determine the degree of influence that prednisone treatment had on the disease course. The patients enrolled in the present study were diagnosed and treated at a facility where prednisone is the first-line therapy for sarcoidosis. After two or three relapses, prednisone is usually withdrawn and methotrexate is prescribed, either as monotherapy or in combination with low doses of prednisone. The multiple linear regression analysis revealed that the chronic sarcoidosis patients treated with the methotrexate-prednisone combination had significantly lower scores for the SHQ domains physical functioning and emotional functioning, as well as lower total SHQ scores, in comparison with the chronic sarcoidosis patients treated with prednisone alone. In addition, compared with the patients receiving the combination therapy, those receiving monotherapy with methotrexate had significantly better SHQ scores for all domains. That is the outstanding finding of this study. Decisions regarding treatment were based on physician perceptions of the severity of the disease. It is possible, in fact, that the patients treated with methotrexate alone exhibited less severe illness than did those treated with the methotrexate-prednisone combination.

We found the SHQ to be a useful instrument for assessing the health status of sarcoidosis patients in Serbia. The questionnaire was successfully translated into Serbian, and the results obtained were similar to those reported for a population of sarcoidosis patients in the United States. In addition, we have demonstrated significant differences in health status for the sarcoidosis patients who were female, as well as for those with the chronic form of the disease and for those in whom the sarcoidosis affected multiple organ systems. Furthermore, we found that monotherapy with methotrexate was associated with better SHQ scores than was monotherapy with prednisone or combination therapy with methotrexate plus prednisone. The SHQ can be a useful tool for comparing health status in sarcoidosis patient populations of various ethnic and geographic origins.
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[^1]: ^a^Values expressed as n (%), except where otherwise indicated.

[^2]: ^a^Values expressed as mean ± SD. \*t-test.

[^3]: SHQ: Sarcoidosis Health Questionnaire; DF: daily functioning; PF: physical functioning; and EF: emotional functioning. ^a^Values expressed as mean ± SD.

[^4]: ^a^Values expressed as mean ± SD. \*ANOVA.

[^5]: ^a^Values expressed as mean ± SD. ^b^Receiving higher daily doses of prednisone. ^c^Receiving lower daily doses of prednisone. \*t-test.

[^6]: SHQ: Sarcoidosis Health Questionnaire; P: prednisone; MTX: methotrexate; and ns: not significant. ^a^Statistics shown as β (p).
